DavidJStrausMD

Hematology • New York, NY

Hematologic Oncology

Professor of Clinical Medicine, Weill Cornell Medical College

Join to view full profile

Dr. Straus is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Straus' full profile

Already have an account?

Office
525 East 72nd Street
18G
New York, NY 10021
Phone+1 646-207-0455

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1975 - 1977
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1972 - 1973
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1969 - 1972
Medical College of WisconsinClass of 1969

Certifications & Licensure

CA State Medical License 1974 - Present
FL State Medical License 2022 - Present
NY State Medical License 1970 - 2025
NJ State Medical License Active through 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Cancer Docters Newsweek, 2015
Top Doctors Castle Connolly, 2015
Super Doctor SuperDoctors.com

Clinical Trials

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Start of enrollment: 1997 Dec 01
Completed
Phase 3
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma Start of enrollment: 2000 Jan 01
Completed
Phase 2
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Start of enrollment: 1999 Dec 01
Completed
Phase 3
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma Start of enrollment: 2001 Oct 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma Start of enrollment: 2004 May 01
Completed
Phase 2
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma Start of enrollment: 2005 Nov 01
Completed
Phase 2
AIDS and Cancer Specimen Bank (ACSB) Start of enrollment: 1997 Jun 01
Completed
Quality of Life Among Survivors of Hodgkin Lymphoma Start of enrollment: 2005 May 01
Completed
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Start of enrollment: 2008 Apr 01
Completed
Phase 1, Phase 2
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Start of enrollment: 2010 May 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-08-01
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.
Kurt S Bantilan, Alexandra N Smith, Matthew J Maurer, Julie Teruya-Feldstein, Matthew J Matasar
Blood Advances. 2024-05-14
1 citations
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-04-01

Journal Articles

CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET
David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood

Abstracts/Posters

Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.
2019 ASCO Annual Meeting - 6/1/2019
Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

ECHELON-1 Update: A+AVD Bests ABVD in Hodgkin LymphomaFebruary 1st, 2020